Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

Also called NCT07091682

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
  • Biotronik AG Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07091682
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany, Hungary, Italy, Latvia, Poland, Spain, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07091682. Allocation not applicable; no masking; primary purpose treatment. Start 2025-02-18 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions
Acronym
BIOMAG-LL
Condition
Atherosclerosis of Coronary Artery
Condition
Myocardial Ischemia
Condition
Ischemic Heart Disease
Condition
Acute Coronary Syndromes
Condition
Angina Pectoris
Intervention (Device)
Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
Lead sponsor
Biotronik AG (class: industry)

Record details

Record id
cardio:ct-nct07091682
Content hash
17198d5f16b1753cc02c616c33c7dd82de7193692106cbe002ba250777d183d1